A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
A phase 2 trial of SI-B001, Paclitaxel / nab-paclitaxel, Docetaxel in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
Overview
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC is a phase 2 interventional study registered as NCT05054439 by Sichuan Baili Pharmaceutical Co., Ltd., with 45 participants enrolled, started 2021-12-22 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B001, Paclitaxel, docetaxel. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
- TrialA Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
- TrialA Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Sq
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
- TrialSI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
Shares SI-B001, SystImmune / Sichuan Biokin, Docetaxel.
- TrialSI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer
Shares SI-B001, SystImmune / Sichuan Biokin.
- TrialA Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares SI-B001, SystImmune / Sichuan Biokin.
- TrialA Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Shares SystImmune / Sichuan Biokin, Docetaxel.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Shares SystImmune / Sichuan Biokin, Docetaxel.